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ABSTRACT
Background: Evidence-based medicine promotes and
relies on the use of evidence in developing clinical
practice guidelines (CPGs). The Chinese healthcare
system includes both traditional Chinese medicine
(TCM) and Western medicine, which are expected to be
equally reflected in Chinese CPGs.
Objective: To evaluate the inclusion of TCM-related
information in Western medicine CPGs developed in
China and the adoption of high level evidence.
Methods: All CPGs were identified from the China
Guideline Clearinghouse (CGC), which is the main Chinese
organisation maintaining the guidelines issued by the
Ministry of Health of China, the Chinese Medical
Association and the Chinese Medical Doctors’ Association.
TCM-related contents were extracted from all the CPGs
identified. Extracted information comprised the institution
issuing the guideline, date of issue, disease,
recommendations relating to TCM, evidence level of the
recommended content and references supporting the
recommendations.
Results: A total of 604 CPGs were identified, only a small
number of which (74/604; 12%) recommended TCM
therapy and only five guidelines (7%) had applied
evidence grading. The 74 CPGs involved 13 disease
systems according to the International Classification of
Diseases 10th edition. TCM was mainly recommended in
the treatment part of the guidelines (73/74, 99%), and
more than half of the recommendations (43/74, 58%)
were related to Chinese herbal medicine (single herbs or
herbal treatment based on syndrome differentiation).
Conclusions: Few Chinese Western medicine CPGs
recommend TCM therapies and very few provide evidence
grading for the TCM recommendation. We suggest that
future guideline development should be based on
systematic searches for evidence to support CPG
recommendations and involve a multidisciplinary approach
including TCM expertise.
INTRODUCTION
Clinical practice guidelines (CPGs) are sys-
tematically developed statements to assist
clinicians and healthcare professionals to
make appropriate clinical decisions in
speciﬁc circumstances. Previous guidelines,
which were mainly based on informal expert
consensus, were inﬂuenced by expert clinical
experience, training and subjective judge-
ment.1 2 With the development of evidence-
based medicine (EBM), guidelines increas-
ingly demand the use of evidence, applying
the principles of EBM to the process of
guideline development. The generation of
guideline recommendations involves both
content and methodology experts, and the
process should be clearly deﬁned and repro-
ducible.3 The commonly used standard that
underpins the development of evidence-
based CPGs was initially developed by the
Scottish Intercollegiate Guidelines Network
(SIGN).4 Over the past decade clinical guide-
lines have increasingly become a familiar
part of clinical practice,5 and over the last
5 years the rate of publication of new CPGs
has increased rapidly in China.6
The China Guideline Clearinghouse
(CGC) is the major resource for CPGs in
China.7 It is jointly initiated and run by the
Evidence-Based Medicine Specialty
Committee under the Chinese Medical
Doctors’ Association and the Chinese
Strengths and limitations of this study
▪ This is the first comprehensive analysis of trad-
itional Chinese medicine (TCM) therapies
included in Western medicine clinical practice
guidelines in China.
▪ The implications for future updating and devel-
opment of Western medicine clinical practice
guidelines involving TCM are highlighted.
▪ There are limitations to this study as guidelines
from other countries that recognise TCM were
not included and a rigorous quality assessment
of all Chinese clinical practice guidelines was not
conducted.
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Medical Association journal board. CGC is an internet
collection of CPGs published in Chinese medical jour-
nals and is used as a platform for clinicians and the
public.
Complementary and alternative medicine (CAM) con-
sists of a wide range of healthcare practices, products
and therapies.8 9 Traditional Chinese medicine (TCM)
is usually considered to be part of CAM in the West and
involves a broad range of medicine practices sharing
common concepts that have been developed in China.
TCM is based on a tradition that has evolved over more
than 3000 years and includes various forms of herbal
medicine, acupuncture, massage (Tuina), exercise
(Qigong) and dietary therapy.10
Western medicine and TCM are parallel and equally
important healthcare systems in China, and the Chinese
government has encouraged the integration of Western
medicine and TCM. Currently, the use of Chinese
patent herbal medicine is widespread and reimbursed
by the government insurance system. Reports have sug-
gested that 60% of Chinese patent herbal medicines are
prescribed by medical doctors in Western medicine hos-
pitals.11 A large-scale survey organised by Beijing
Municipal Administration of Traditional Chinese
Medicine and Beijing Association of Chinese Medicine
found that 40% of prescriptions of patent herbal medi-
cine by Western medicine doctors was inappropriate due
to lack of TCM knowledge.11
This study aims to assess the status of TCM recom-
mended as an intervention in Western medicine CPGs
in China and the use of evidence that underpins these
recommendations. Our purpose in doing this is to
provide an appropriate evidence-based strategy for the
development of Western medicine CPGs that include
TCM.
METHODS
Inclusion criteria
Guidelines approved and issued by the Ministry of
Health of China, the Chinese Medical Association and
the Chinese Medical Doctors’ Association were all
included in the initial review. Subsequently, all CPGs
containing TCM were included in the study. Older ver-
sions of the guidelines with existing updates were
excluded.
Data sources
CPGs were identiﬁed from the CGC from 2004 (when
the ﬁrst guideline was issued in China) to 14 January
2013. A supplementary search of CPGs was conducted
up to 30 August 2014 in the China National Knowledge
Infrastructure (CNKI), Chinese Scientiﬁc Journal
Database (VIP) and Wan Fang database. The search
strategy and search terms used were as follows: (‘clinical’
(linchuang) or ‘prevention’ or ‘practice’ or ‘treat’ or
‘operation’ or ‘pharmacy’ or ‘drug’ or ‘treatment’) and
(‘guideline’ or ‘standard’ or ‘proposal’ or
‘recommendation’ or ‘consensus’ or ‘criterion’) and
(‘Ministry of Health of the People’s Republic of China’
or ‘Chinese Medical Association’ or ‘Chinese Medical
Doctor Association’).
Data extraction
Any mention of the term ‘TCM’ in the included guide-
lines was regarded as having TCM-related content.
Three authors ( JR, JS and WYL) extracted the following
information relating to TCM: the organisation issuing
the guideline, date of issue, disease, location in guide-
lines of TCM content, recommended TCM content, evi-
dence level of the recommendation and references
supporting the recommendations. Data were extracted
onto a Microsoft Excel 2010 spreadsheet for data
manipulation.
Data analysis
Frequency data were generated for descriptive statistical
analysis using Microsoft Excel 2010.
RESULTS
A total of 604 CPGs were identiﬁed and issued by three
organisations between 2004 and 2014, and 74 guidelines
(12%) mentioned TCM (table 1 and online supplemen-
tary ﬁle).12–85 Over the past 10 years there was an overall
increase in the number of CPGs, but there was no sig-
niﬁcant increase in those with TCM content (ﬁgure 1).
The number of published guidelines including TCM
content reached its maximum between 2010 and 2014,
peaking at 16 new guidelines in 2013 (complete data for
2014 are not currently available). The ﬁrst guideline to
recommend TCM was published in 2005 (ﬁgure 1).
Subsequent analysis of the 604 CPGs according to the
International Classiﬁcation of Diseases, 10th edition
(ICD-10) identiﬁed 21 disease systems. Of the 74 guide-
lines with TCM content, 58 different diseases were iden-
tiﬁed and these involved 13 speciﬁc disease systems
(ﬁgure 2).
Table 1 Distribution of Western medicine clinical
practice guidelines among three organisations
Name of organisation
No of
CPGs
No of CPGs
recommending
TCM (%)
Chinese Medical
Association
526 61* (12%)
Chinese Medical
Doctors Association
47 4* (9%)
Ministry of Public
Health
35 9* (26%)
Total 604 74 (12%)
*This excludes those jointly issued by multiple agencies and old
version guidelines with existing updated ones.
CPG, clinical practice guideline; TCM, traditional Chinese
medicine.
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In the 74 CPGs with TCM content, one mentioned
TCM in the introduction (1%), one in the diagnosis of
syndrome differentiation (1%), but most of the guide-
lines mentioned TCM in the treatment recommendation
section (73, 99%). In addition, TCM recommendations
were described under prevention (three guidelines,
occupying 4% of the total guideline number) and two
under rehabilitation (3%). Five guidelines mentioned
TCM in more than one section of the guideline.
Among the 74 CPGs with TCM content, 43 guidelines
(58%) recommended a Chinese herbal treatment
(including single herbs or multiple herbs based on syn-
drome differentiation) and, among them, 25 guidelines
(34%) recommended Chinese proprietary medicine or
herbal preparations produced by a hospital pharmacy
and not necessarily approved by the State Food and Drug
Administration. In addition, 14 guidelines (19%) recom-
mended acupuncture, one guideline recommended acu-
puncture point injection (1%) and 14 guidelines
recommended two or more TCM therapies (table 2).
Of the 74 CPGs with TCM content, only ﬁve guide-
lines (7%) provided evidence grading for the TCM
recommendations.50 51 53 54 56 Three guidelines
reported level I evidence related to TCM,50 53 54 four
guidelines reported level II evidence related to acupunc-
ture and herbal extracts41 53 54 58 and three guidelines
reported level III evidence related to Chinese patent
medicine and massage.53 54 64 All these guidelines speci-
ﬁed the herbal compositions (table 3).
Two of the 74 CPGs with TCM content mentioned
that “due to the limited literature involving TCM studies
and small sample sizes, more evidence was needed
before making ﬁrm recommendations” and “further
high-quality studies should be conducted to conﬁrm the
effects of TCM treatments”.51 53 Three guidelines did
not provide further comments after recommending
TCM treatments.50 52 58 The other 69 guidelines did not
provide the evidence level for their recommendation for
TCM treatments, but only listed a general statement—
for example, “TCM treatment: apply TCM treatment
methods such as herbal medicines, acupuncture, acu-
point injection, and Tuina, which should be based on
syndrome differentiation”.20
Of the 74 CPGs with TCM content, only 11 mentioned
appropriate references to TCM such as systematic
reviews (n=3),51 53 71 randomised controlled trials
(n=6),17 50 51 54 58 71 non-randomised controlled trials
(n=2),54 58 case series (n=4)24 51 54 71 or other (n=1)
(historical TCM classical texts).82
DISCUSSION
Few Western medicine CPGs in China recommended
TCM, and very few guidelines applied an evidence-based
approach in the recommendations. The majority of the
TCM therapies (58%) recommended were Chinese
herbal medicine, and about 59% of the recommenda-
tions were for chronic diseases such as chronic hepatitis
B, bronchial asthma and type 2 diabetes mellitus. The
TCM content of the 74 CPGs failed to provide adequate
references to research published in international jour-
nals. In addition, the methodology regarding how the
TCM recommendations were formulated was not trans-
parent or evidence-based.
This study systematically assessed the status of TCM
therapy recommended in 604 Western medicine CPGs
issued by three state level organisations in China. To the
best of our knowledge, this is the ﬁrst comprehensive
analysis detailing the inclusion of TCM content in
Western medicine CPGs published in China.
Recommendations for TCM in the current Chinese
guidelines are not reﬂected by its popularity in practice.
The ﬁndings of this study provide insights for the future
development and updating of CPGs involving Western
medicine and TCM in China.
This study has some limitations. First, the included
guidelines were all identiﬁed from the China Guideline
Clearinghouse and issued by the Ministry of Health, the
Chinese Medical Association and the Chinese Medical
Doctors’ Association. These guidelines are easily
Figure 1 Number of clinical practice guidelines approved in China. The figure shows the trend among Western medicine clinical
practice guidelines (CPGs) with respect to traditional Chinese medicine (TCM) content in the period 2004–2014.
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accessible and published centrally but may not be com-
prehensive as some guidelines may be issued by other
relevant Chinese professional societies. Second, we did
not include guidelines from other countries that recog-
nise TCM (eg, the use of acupuncture for pain in the
USA and Europe) so we are unable to comment about
the speciﬁc evidence for TCM in treatment guidelines in
other countries. Third, we only evaluated evidence
grading in those CPGs that recommended TCM so we
are not able to reach any conclusions about the CPGs
that did not recommend TCM.
This study shows that Western medicine CPGs do not
include adequate relevant research to support the guide-
lines’ recommendations for TCM. It appears that trials
and systematic reviews carried out in the West may not
be included as evidence even though the research may
be of good quality. One article published in 2014 identi-
ﬁed 13 guidelines and 22 systematic reviews issued by
East Asian countries on traditional medicine (including
acupuncture, moxibustion, cupping, herbal medicine,
TCM, manual therapy and Tuina) for low back pain.87
This study suggested that the current CPGs do not fully
reﬂect the evidence for traditional medicine interven-
tions and concluded that, as relevant studies, systematic
reviews and meta-analyses are conducted and the evi-
dence increases, the current evidence on acupuncture,
herbal medicine and manual therapy should be recon-
sidered in the process of developing or updating rele-
vant CPGs. Similarly, in the UK, a recent study of NHS
Western medical clinical guidelines issued by the
National Institute for Health and Care Excellence
demonstrated a low proportion of CPGs mentioning at
least one CAM.88 Out of 279 UK clinical guidelines
issued during 2006–2013, only 16% mentioned CAM,
with acupuncture and natural herbal medicines being
the most common. For acupuncture, six guidelines
recommended its use, three stated that it could be con-
sidered but the evidence was weak, 18 could not recom-
mend acupuncture based on the available evidence and
six advised against the use of acupuncture. Thirty-six
guidelines mentioned the use of various natural pro-
ducts including herbs. Interestingly, there were more
guidelines mentioning acupuncture in the UK than
there were in China over the same time period.88
Our study shows that there is insufﬁcient application of
TCM research evidence in Western medicine guidelines
in China. This may be because the guideline developers
did not identify the relevant evidence when preparing
the guidelines, but it is important to note that most of the
guidelines did not have clear methodology for how they
had been developed. One recent study reported that
there were 2964 controlled clinical trials involving TCM
in cancer treatment published in China between1984
and 2011, and the number of such publications increases
annually, but these data do not seem to have been used
in guideline development.89 For instance, Cao et al90
identiﬁed 550 Chinese clinical studies on cupping
therapy published between 1959 and 2008 but, again,
these did not attract adequate attention in the ﬁeld of
guideline development. A large number of reviews on
TCM have reported a high level of interest,91 but there is
little or no reliable evidence with positive ﬁndings for
Figure 2 Categories of diseases involved in clinical practice guidelines in China. The figure shows the number of disease
categories involved in the total number of clinical practice guidelines (CPGs) and Chinese Western medicine CPGs with related
traditional Chinese medicine (TCM) content, respectively.
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CAM including TCM mainly due to the poor methodo-
logical quality of the original studies.92 Thus, whether
there is adequate evidence to recommend TCM in guide-
lines included in this study is still not known, and this
should be the focus of future research.
In spite of these caveats, it appears that (1) there is
insufﬁcient evidence to recommend TCM for some con-
ditions and further research is required; (2) the evi-
dence on the quality, safety and efﬁcacy of traditional
medicine does not meet the applicable standards for
Western medicine;93 and (3) Chinese guidelines are gen-
erally of poor quality and have mostly been developed
through expert consensus and lack rigorous scientiﬁc
methodology.94
Based on the ﬁndings from our study, we make the fol-
lowing suggestions for the future development of
Chinese clinical guidelines. First, all guidelines should
be evidence-based so that the recommendations can be
supported by research evidence. Adopting an evidence-
based approach to the development of CPGs has
become an international trend,4 and CPGs should be
founded on the highest quality of scientiﬁc evidence
available. In the Chinese context (reﬂecting the
popularity of TCM), considerable effort should be made
to look at both Western medicine and TCM to reﬂect
and support their clinical use. Second, many of the ori-
ginal Chinese studies are of poor quality, challenging
their utility as evidence in China and abroad,95 and
there is an urgent need to improve the methodology
and reporting of randomised controlled trials in China.
Third, different stakeholders should be involved in the
development of CPGs such as Western medical doctors,
TCM practitioners, methodologists, information person-
nel, nurses and healthcare policy makers.96
CONCLUSIONS
TCM is included in 12% of Western medicine guidelines
in China. Few guidelines that recommend TCM provide
references, and very few have applied evidence grading
to support their recommendations. Future guideline
development in China should be based on internation-
ally recognised methodology with relevant stakeholders
involved. We suggest systematic searching and synthesis-
ing of evidence, critical appraisal of evidence, and report-
ing the evidence with reference to the Grading of
Table 2 Traditional Chinese medicine therapy recommended in Western medicine clinical practice guidelines
TCM therapy
No of
CPGs Diseases involved (no of guidelines if >1)
Chinese
herbal
medicine
Single herb, treatment based on
syndrome differentiation
43 Chronic hepatitis B (3), bronchial asthma (3), nasosinusitis
(2), chronic obstructive pulmonary disease (2), type 2
diabetes mellitus (2), allergic rhinitis, avascular necrosis of the
femoral head, common kidney disease in children, childhood
diarrhoea, hepatolenticular degeneration, osteoporotic
fracture, heart failure, colorectal cancer, influenza, difficult
asthma, pelvic inflammatory disease, spleen injury, spleen
retained, prostatitis, eczema, baby allergic disease, primary
hepatic carcinoma, haemorrhoids, obesity, psoriasis, severe
acute pancreatitis, spinal cord injury, colorectal cancer,
drug-induced liver injury, limb atherosclerosis, inflammatory
bowel disease, vasomotor rhinitis, acute pancreatitis, chronic
constipation, influenza, hand-foot-and-mouth disease, optic
neuritis, chronic venous disease
Chinese proprietary medicine* or
traditional Chinese preparation†
25 Cerebrovascular disease (2), primary liver cancer (2),
dementia and cognitive impairment (2), viral hepatitis,
gastrointestinal disease, Behcet syndrome, adult onset Still’s
disease, rheumatoid arthritis, influenza, Malassezia-
associated diseases, eczema, vascular cognitive impairment,
bronchial asthma, type 2 diabetes mellitus, acute ischaemic
stroke, psoriasis, management of menopause, nasosinusitis,
influenza, hand-foot-and-mouth disease, acute paraquat
poisoning, fatty liver disease
Acupuncture and/or moxibustion 14 Stroke (2), irritable bowel syndrome, childhood diarrhoea,
prostatitis, fibromyalgia syndrome, haemorrhoids, adult
insomnia, acute ischaemic stroke, migraine, management of
menopause, chronic constipation, child autism, acne
Acupuncture point injection 1 Childhood diarrhoea
*Chinese patent medicine, Chinese herbal preparation or Chinese herb extracts.
†The forms were unspecified.
As one guideline may recommend more than one kind of TCM therapy, the total number of guidelines involved is larger than 74.
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Table 3 Recommendations based on evidence level for traditional Chinese medicine content in Western medicine clinical practice guidelines
Recommendation
level Guideline title Treatment Recommendation contents
Level I Chinese guidelines on diagnosis and
management for cognitive impairment and
dementia
Chinese herbal preparation Ginkgo leaf preparation has a mild effect in slowing down memory in older patients
(grade A evidence).
Does not stop or slow down the development from MCI to dementia (grade A
evidence)
Chinese guidelines on rehabilitation treatment for
stroke (2011 full version)*
Traditional Chinese
medicine
For stroke rehabilitation, traditional Chinese medicine therapies can be added to
conventional rehabilitation therapy (grade A evidence)
Guidelines on management for stroke
rehabilitation (Simplify)†
Traditional Chinese
medicine
In the rehabilitation process of stroke, traditional Chinese medical therapies can be
included as part of conventional rehabilitation therapy (grade A evidence)
Level II Chinese guidelines on prevention and treatment
for acute ischaemic stroke (2010)
Acupuncture Decision to choose acupuncture should take into account the patient’s willingness to
have acupuncture (level II recommendation, grade B evidence)
Chinese guidelines on rehabilitation treatment for
stroke (2011 full version)
Guidelines on the management for stroke
rehabilitation (Simplify)
Acupuncture
Acupuncture
Acupuncture can speed up physical recovery and improve motor ability during the
flaccid paralysis stage of stroke patients (level II recommendation, grade B
evidence).
Acupuncture may be used in bulbar paralysis patients (level II recommendation,
grade B evidence).
Acupuncture may be used for bulbar paralysis patients (level II recommendation,
grade B evidence)
Chinese guidelines on diagnosis and
management for cognitive impairment and
dementia (V): dementia therapy
Chinese herbal medicine
and Chinese herbal
preparation
Ginkgo leaf may improve the neuropsychic symptoms and slow down the disease
progression of dementia (grade B evidence).
Ginkgo leaf extract does not reduce the incidence of AD in elderly people with mild
cognitive impairment (grade B evidence). Salvia officinalis extract is able to improve
cognitive function in mild and moderate AD patients and relieve the symptoms of
agitation (grade B evidence)
Level III Chinese guidelines on prevention and treatment
for acute ischemic stroke (2010)
Chinese patent medicine Decision to use acupuncture (level II recommendation, Grade B evidence) should
take patient’s willingness into consideration,
Chinese proprietary medicine (level III recommendation, grade C evidence)
Chinese guidelines of rehabilitation treatment for
stroke (2011 full version)
Massage Recommendation of massage for patients with severe limb spasm to relieve fatigue
and muscular tension (level III recommendation, grade C evidence)
Chinese guidelines on rehabilitation treatment for
stroke (2011 full version)
Massage Recommendation of massage for patients with severe limb spasm to relieve fatigue
and muscular tension (level III recommendation, grade C evidence)
Quality evidence based on GRADE: A, high quality; B, moderate quality; C, low quality; D, very low quality.
Quality level based on GRADE:
1. High: we are very confident that the true effect lies close to that of the estimate of the effect.
2. Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect but there is a possibility that it is substantially different.
3. Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
4. Very low: we have very little confidence in the effect estimate; the effect is likely to be substantially different from the estimate of effect.
*Although the two articles have partially similar content, we regarded them as different guidelines because of different form and part of the content.
†If level of evidence involved did not identify a specific standard, it was assessed based on GRADE standards.86
AD, Alzheimer’s disease; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; MCI, mild cognitive impairment.
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